Mission and vision

Founded as a spin-off of the globally recognized Institut Pasteur of Paris, Oncovita is an early-stage biotech company dedicated to the development of new life-saving treatments and vaccines, in particular anti-cancer therapies. Oncovita is developing a pipeline of candidates based on a disruptive technology and its proprietary platform MeasovirTM. The technology engineers select changes in the measles viral genome designed to dramatically increase its anti-tumor properties. This “plug-and-play” platform allows producing immuno-oncolytic drug candidates. Oncovita has been granted the exclusive intellectual property rights for developing, manufacturing and marketing all oncology applications. Our mission is to develop these products from preclinical to clinical proof-of-concept to every patient’s bedside.



Management team

Board of Directors

Scientific Advisory Board